Onconetix, Inc. filed a Form 8-K on November 12, 2026, reporting the voting results from its 2026 annual meeting of stockholders held on November 10, 2026, at which all five proposals on the ballot were approved.

Key Highlights

  • All five proposals approved: Stockholders voted in favor of every matter presented at the November 10, 2026 annual meeting, according to the filing.
  • Director elected: Josh Epstein was elected as a Class II director for a three-year term expiring at the 2029 Annual Meeting of Stockholders.
  • Series F PIPE share issuance approved: Stockholders approved the issuance of up to 154,856,150 shares of Common Stock upon conversion of Series F Preferred Stock, with 1,074,708 votes for and 195,729 votes against.
  • Reverse stock split authority granted: The Board received discretionary authority to effect a reverse stock split at a ratio in the range of 1-for-2 to 1-for-15, to be completed no later than one year after the annual meeting date.
  • Auditor ratified: MaloneBailey, LLP was ratified as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, receiving 2,164,067 votes for.
  • Record date shares: The aggregate shares of Common Stock outstanding as of September 29, 2026, the record date, were 5,241,486.

Onconetix 2026 Annual Meeting Results: Directors, Share Issuance, and Split Authority

Onconetix, Inc. (NASDAQ:ONCO) disclosed the results of its 2026 annual meeting of stockholders in a current report filed November 12, 2026. According to the filing, the meeting was held on November 10, 2026, with five matters submitted to a vote. All five were approved based on 5,241,486 shares of Common Stock outstanding as of the September 29, 2026 record date.

On the Director Election Proposal, Josh Epstein received 1,236,372 votes for, zero votes against, 39,010 abstentions, and 969,149 broker non-votes, the filing stated. He will serve as a Class II director until the 2029 Annual Meeting of Stockholders, or until his successor is elected and qualified. The Series F PIPE Proposal, which concerned the issuance of up to 154,856,150 shares of Common Stock upon conversion of Series F Preferred Stock issued in a private placement that the filing noted closed on July 29, 2026, received 1,074,708 votes for, 195,729 against, 4,945 abstentions, and 969,149 broker non-votes.

The Reverse Stock Split Proposal, granting the Board discretionary authority to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-15, with the exact ratio to be set by the Board in its sole discretion, received 1,789,725 votes for, 448,644 against, and 6,162 abstentions. The filing noted the split must be completed no later than the one-year anniversary of the annual meeting. The Auditor Ratification Proposal, covering MaloneBailey, LLP for the fiscal year ending December 31, 2026, received 2,164,067 votes for, 58,652 against, and 21,812 abstentions. The Adjournment Proposal received 1,913,865 votes for, 310,779 against, and 19,887 abstentions.

What Was Disclosed

Onconetix reported the final voting results from its November 10, 2026 annual stockholder meeting, covering director election, a large common stock issuance tied to Series F Preferred Stock conversion, reverse stock split authority, auditor ratification, and an adjournment proposal, all of which passed.